Advanced search
Publication Cover
Scandinavian Journal of Rheumatology Volume 51, 2022 - Issue 2
Submit an article Journal homepage
2,327
Views
3
CrossRef citations to date
0
Altmetric
Articles/Brief Reports

Comparison of outcomes using the rituximab originator MabThera with the biosimilar Truxima in patients with ANCA-associated vasculitis

M Antonelou1 Department of Renal Medicine, Royal Free Hospital, University College London, London, UKCorrespondence[email protected]
,
A Abro1 Department of Renal Medicine, Royal Free Hospital, University College London, London, UK
,
R Heath1 Department of Renal Medicine, Royal Free Hospital, University College London, London, UK
,
A Iacovou1 Department of Renal Medicine, Royal Free Hospital, University College London, London, UK
,
C Ashley1 Department of Renal Medicine, Royal Free Hospital, University College London, London, UK;2 Pharmacy Department, Royal Free Hospital, London, UK
,
J Caplan3 Department of Renal Medicine, University Hospital Birmingham, Birmingham, UK
,
MD Morgan3 Department of Renal Medicine, University Hospital Birmingham, Birmingham, UK
,
S Logan3 Department of Renal Medicine, University Hospital Birmingham, Birmingham, UK
,
L Harper3 Department of Renal Medicine, University Hospital Birmingham, Birmingham, UK
&
AD Salama1 Department of Renal Medicine, Royal Free Hospital, University College London, London, UK
 show all
Pages 135-141 | Accepted 03 May 2021, Published online: 02 Sep 2021

References

  • Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1–11.
  • Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211–20.
  • Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 2015;54:1153–60.
  • Walsh M, Merkel PA, Peh CA, Szpirt W, Guillevin L, Pusey CD, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013;14:73.
  • Charles P, Perrodeau É, Samson M, Bonnotte B, Néel A, Agard C, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody–associated vasculitis. Ann Intern Med 2020;173:179–87.
  • Smith RM, Jones RB, Specks U, Bond S, Nodale M, Aljayyousi R, et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 2020;79:1243–9.
  • Gulácsi L, Brodszky V, Baji P, Rencz F, Péntek M. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther 2017;34:1128–44.
  • EMA. Assessment report: Truxima. International non‐proprietary name: rituximab (2016). Procedure No. EMEA/H/C/004112/0000. EMA/CHMP/75695/2017. London, UK: European Medicines Agency, 2016. https://www.ema.europa.eu/documents/assessment-report/truxima-eparpublic-assessment-report_en.pdf.
  • Hendra H, Salama AD. Steroids as treatment for glomerulonephritis: time for a rethink. Nephrol Dial Transplant 2020;gfaa267. doi:https://doi.org/10.1093/ndt/gfaa267. Online ahead of print.
  • Kwon HC, Kim MK, Song JJ, Park YB, Lee SW. Rituximab biosimilar prevents poor outcomes of microscopic polyangiitis and granulomatosis with polyangiitis as effectively as rituximab originator. Yonsei Med J 2020;61:712–9.
  • Mittal S, Naidu GSRSNK, Jha S, Rathi M, Nada R, Minz RW, et al. Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis-a real-life experience. Clin Rheumatol 2021;40:645–51.
  • Coiffier B. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10. Expert Rev Clin Pharmacol 2017;10:923–33.
  • Stubbs MJ, Low R, McGuckin S, Newton R, Thomas M, Westwood JP, et al. Comparison of rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura. Br J Haematol 2019;185:912–7.
  • Perez T, Rico A, Boutière C, Maarouf A, Roudot M, Honoré S, et al. Comparison of rituximab originator (MabThera®) to biosimilar (Truxima®) in patients with multiple sclerosis. Mult Scler 2020;27:1352458520912170.
  • McAdoo SP, Bedi R, Tarzi R, Griffith M, Pusey CD, Cairns TD. Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series. Rheumatology (Oxford) 2016;55:1437–42.
  • Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open 2016;1:e000142.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.